DURHAM, NC, GeneCentric Therapeutics, an RNA-based diagnostics startup, raised $7.5 million Series B1 financing.
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million.
New investors include IAG Capital Partners and Alexandria Venture Investments, along with existing investors Labcorp and Hatteras Venture Partners.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
